Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

Latest Trials

Systemic therapy trial

Vivace : Phase 1, Multi-Center, Open-Label, Study to Evaluate the Safety, Tolerability, and PK of...

This Phase I trial is trying to understand how safe and tolerable a targeted therapy drug (VT3989) is in people with advanced pleural malignant mesothelioma or other metastatic solid tumours

Status : Recruiting

Systemic therapy trial

A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety,...

This phase I/II study is evaluating how safe, tolerable and effective a new cancer drug (AZD8205) is in people with advanced or metastatic solid cancers

Status : Recruiting

Systemic therapy trial

Lynk 003 : A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib...

This phase III trial is trying to evaluate the safety and effectiveness of a targeted cancer drug, given alone and in combination with another targeted cancer drug or chemotherapy, for the treatment of patients with a colorectal cancer that has spread to other parts of the body

Status : Recruiting

Systemic therapy trial

CERPASS : A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and...

This phase II trial is assessing the benefits of using a targeted therapy (cemiplimab) in combination with a biological therapy (RP1) to treat patients with advanced or metastatic cutaneous squamous cell carcinoma

Status : Recruiting

Systemic therapy trial

MONETTE : A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib Plus...

This phase II study is evaluating how safe, tolerable and effective targeted therapy (ceralasertib) is alone, and in combination with immunotherapy (durvalumab), in people with inoperable or advanced melanoma and primary or secondary resistance to PD(L)1 Inhibition

Status : Recruiting

Systemic therapy trial

I-FIRST : A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR...

This phase II trial will use Dabrafenib and/or Trametinib to enhance treatment for people with thyroid cancer who no longer respond to radioactive iodine (a standard treatment for people with this type of cancer)

Status : Recruiting

Multiple treatment types

SKYSCRAPER 5 : A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of...

This phase II study is evaluating safety and feasibility of combination immunotherapy (atezolizumab + tiragolumab) alone, or in combination with platinum-based chemotherapy, as treatment prior to surgery in people with previously untreated locally advanced non-small cell lung cancer

Status : Recruiting

Systemic therapy trial

PACIFIC-9 : A Phase III, Double-blind, Placebo-controlled, Randomised, Multicentre, International...

This phase III trial is testing different combinations of targeted therapy in people with locally advanced non-small cell lung cancer that has not progressed on prior chemoradiotherapy treatment and is unable to be surgically removed

Status : Recruiting

Systemic therapy trial

BREAKWATER : AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS...

This phase III trial is evaluating whether targeted therapy, alone or in combination with chemotherapy, is more effective than standard care in patients with metastatic colorectal (bowel) cancer

Status : Recruiting

Systemic therapy trial

SURF301 : A Multicenter, Open-label Phase 1/2 Study of TYRA300 in Advanced Urothelial Carcinoma and...

This phase I/II study is evaluating how safe, tolerable and effective a new drug (TYRA-300) is in people certain cancers with FGFR3 activating gene alterations

Status : Recruiting

 

Looking for a trial? Use the search functionality to find the trial you are finding.